Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Phase 2 Completed 280 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.

Timeline

Start: 2011-05
Primary completion: 2012-06
Completion: 2012-06

Publications

Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015 May;27(5):705-16. doi: 10.1111/nmo.12544. Epub 2015 Mar 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bacillus subtilis	Vaccine	10 unknown	Oral
Subject	Bacillus subtilis	Vaccine	15 unknown	Oral
Subject	Bacillus subtilis	Vaccine	30 unknown	Oral
Subject	Mosapride	Small molecule	10 mg	Oral
Subject	Mosapride	Small molecule	15 mg	Oral
Subject	Streptococcus faecium	Unknown	10 unknown	Oral
Subject	Streptococcus faecium	Unknown	15 unknown	Oral
Subject	Streptococcus faecium	Unknown	30 unknown	Oral

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Summary

Timeline

Publications

Drugs

Indications